Dr. Eleftherios Diamandis, a researcher at Toronto’s Mount Sinai Hospital, would like a better alternative that could reduce unnecessary biopsies.
Dr. Diamandis plans to spend the next two years developing a non-invasive test that can help determine when high PSA levels warrant concern. To do this, he will zero in on genetic mutations found in the semen of men with prostate cancer and use those biomarkers to screen other men for the disease.